Delivery Order SPE2DB22D3016-SPE2DB24FBCJ9
Award Date
7/29/24
Potential Completion Date
8/19/24
Potential Value
$23K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, issued by the Defense Logistics Agency (DLA), provides for the delivery of OCREVUS 300 mg/10 ml vials to the government. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, in the amount of $23,118.08. The contract is a Firm Fixed Price Delivery Order, with a completion date of May 31, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00...
This federal contract award, valued at $46,236.16, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a critical prescription medication, to support DLA's medical supply chain. The contract has an ultimate completion date of September 20, 2024 and is a Firm Fixed Price Delivery Order. This award is likely part of a larger Indefinite Delivery Contract (IDC) that...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of OCREVUS 300 mg/10 mL vials. The delivery order, valued at $23,118.08, has an ultimate completion date of April 22, 2024. This award is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a period of performance through...
This federal contract award, with a ceiling value of $24,038.58, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product, with a period of performance through June 4, 2025. The contract is a Delivery Order and is Firm Fixed Price. The award is not set-aside and was an open competition. Amerisourcebergen Drug...
This federal contract award is for the delivery of OCREVUS 300 MG/10 ML vials to the Defense Logistics Agency (DLA), a defense agency. The $47,834.16 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on November 20, 2024. The contract has an ultimate completion date of December 12, 2024 and is not set aside for any specific business type. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract valued at $46,236.16 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide 4565153318 OCREVUS 300 MG/10 ML VIAL 10ML. This order is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued up to $999,999,999.00 through December 31, 2025, to deliver a broad range of pharmaceutical products and medical supplies in support of the Department of...
This federal contract award, valued at $71,751.24, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
This federal contract award, issued by the Defense Logistics Agency (DLA), was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,038.58, is a delivery order for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of March 24, 2025 and is a firm fixed-price contract. The contract is not designated with a set-aside requirement, indicating open...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to the Corporate Office division of Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide OCREVUS 300 MG/10 ML VIAL 10ML. The $23,118.08 contract has a June 3, 2024 ultimate completion date. This award is made under Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $180,289.20 firm fixed-price delivery order is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription medication. The contract has an ultimate completion date of June 4, 2025. This award is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...